-
Hybribio’s Chloroquine Phosphate Gel Cleared for Clinical Trial on High-Risk HPV Infections
•
Hybribio Limited (SHE: 300639), a Guangdong-based pharmaceutical company, has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for its chloroquine phosphate gel, a patented pharmaceutical preparation in China. The gel, designed for topical administration, is intended to reduce systemic exposure and is formulated…
-
Ocumension Therapeutics’ OT-502 Receives NMPA Acceptance for Post-Cataract Inflammation Treatment
•
Ocumension Therapeutics (HKG: 1477) announced on September 23, 2024, that the National Medical Products Administration (NMPA) in China has accepted its New Drug Application (NDA) for OT-502 (DEXYCU, dexamethasone implant). This ophthalmic new drug is designed to treat postoperative inflammation and is indicated for suppressing inflammation and related complications in…
-
Yantai Dongcheng Pharmaceutical’s 18F-LNC1007 Receives Clinical Clearance for Solid Tumor Diagnostics
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has received clinical trial approval from the National Medical Products Administration (NMPA) for its 18F-LNC1007 injection, a novel radioactive diagnostic drug. This drug is designed to target fibroblast activating protein (FAP) and integrin alpha-v beta-3, which are biomarkers…
-
Fosun Pharmaceutical’s PD-1 Inhibitor HanSiZhuang Recommended for Approval by EMA’s CHMP
•
Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196), a leading pharmaceutical company in China, has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending the approval of its anti-programmed death-1 (PD-1) inhibitor, HanSiZhuang, in combination with carboplatin and…
-
Tencent’s We Doctor Partners with CHA on National Digital Health Platform and Academic Initiatives
•
We Doctor, a subsidiary of Chinese internet conglomerate Tencent Corporate Venture Capital (HKG: 0700) specializing in online medical services, has entered into a strategic partnership with the Chinese Health Association (CHA). The collaboration aims to explore innovative models focused on ‘common health’ and ‘universal health.’ As part of this initiative,…
-
Huadong Medicine Secures Exclusive Rights to Janagliflozin for Type 2 Diabetes Treatment in China
•
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has entered into a licensing agreement with fellow Chinese firm Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), securing exclusive commercialization rights for Sihuan’s Category 1 drug, janagliflozin, in mainland China. Under the terms of the agreement, Huadong will handle the…
-
Beijing Aims to Establish Rare Disease Drug Security Pilot Zone with ‘White List’ System
•
Beijing is set to follow in the footsteps of Boao Lecheng with the release of the “Implementation Plan for Promoting the Construction of Rare Disease Drug Security Pilot Zone in Beijing (Trial) (draft proposal),” which concluded its public feedback period on August 13. The two-year policy initiative aims to establish…
-
Beijing Authorities Release Negative List for Data Export in Key Industries
•
Authorities in Beijing, including the Beijing Municipal Bureau of Commerce and the Beijing Municipal Service and Data Administration, have issued the ‘Management Measures for Negative List of Data Export from China (Beijing) Pilot Free Trade Zone (Trial)’ and the ‘Management List of Data Export from China (Beijing) Pilot Free Trade…
